Vaxart Inc (NASDAQ: VXRT) shares are trading higher on Monday after B Riley FBR initiated coverage on the company's stock with a Buy rating and announced a $22 price target.
The company also raised about $90 million in gross proceeds through at-the-market-facility.
Vaxart is a biopharmaceutical company. It is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally.
The company has three product candidates which are; Influenza, Norovirus and RSV Vaccine, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in for condyloma caused by human papillomavirus. Geographically all the business activity is functioned through the region of the US.
Vaxart shares were trading up 50.25% at $11.99 at the time of publication on Monday. The stock has a 52-week high of $14.30 and a 52-week low of 25 cents.
Latest Ratings for VXRT
|Jul 2020||B. Riley FBR||Initiates Coverage On||Buy|
|Apr 2020||HC Wainwright & Co.||Reiterates||Buy|
|Jun 2019||H.C. Wainwright||Initiates Coverage On||Buy|
View More Analyst Ratings for VXRT
View the Latest Analyst Ratings
See more from Benzinga
- 4 Cybersecurity Investment Opportunities Tied To The Rise In Online Threats
- With E-Commerce Shift Underway, BofA Has High Expectations For PayPal's Q2
- Why Herbalife's Stock Is Trading Higher Today
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.